Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those...
